AngioDynamics, Inc. (NASDAQ:ANGO) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Broker sentiment is mixed: AngioDynamics has a consensus “Hold” rating from five analysts, including two sells, two buys, and one strong buy. The average one-year price target is $19.50 versus a recent share price of $15.44.
• Recent results exceeded expectations: The company reported quarterly revenue of $86.61 million and an adjusted loss of $0.07 per share, beating analyst estimates of $80.24 million and a $0.11 loss, respectively.
• Ownership activity was notable: An executive sold 23,370 shares, while institutional investors own 89.43% of the stock. BlackRock and other investment firms recently established or increased positions.

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $19.50.

ANGO has been the subject of a number of recent research reports. HC Wainwright boosted their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. Canaccord Genuity Group raised their target price on AngioDynamics from $16.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of AngioDynamics in a research report on Friday, July 17th. Zacks Research cut AngioDynamics from a "hold" rating to a "strong sell" rating in a research report on Thursday, July 16th. Finally, Wall Street Zen raised AngioDynamics from a "hold" rating to a "buy" rating in a research note on Saturday, August 22nd.

AngioDynamics Stock Up 0.5%

Shares of NASDAQ:ANGO opened at $15.44 on Friday. The stock has a market capitalization of $638.14 million, a PE ratio of -17.75 and a beta of 0.33. The firm's 50 day moving average price is $15.08 and its 200-day moving average price is $12.69. AngioDynamics has a twelve month low of $9.39 and a twelve month high of $16.29.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. Analysts expect that AngioDynamics will post -0.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the company's stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On AngioDynamics

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of AngioDynamics during the second quarter valued at approximately $49,480,000. Armistice Capital LLC increased its holdings in AngioDynamics by 3.9% in the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier's stock valued at $21,828,000 after acquiring an additional 64,000 shares during the last quarter. Weber Capital Management LLC ADV bought a new stake in AngioDynamics in the 2nd quarter valued at $17,649,392. Royce & Associates LP lifted its stake in AngioDynamics by 27.3% in the 4th quarter. Royce & Associates LP now owns 1,267,451 shares of the medical instruments supplier's stock worth $16,274,000 after purchasing an additional 272,091 shares in the last quarter. Finally, Bastion Asset Management Inc. lifted its stake in AngioDynamics by 17.4% in the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier's stock worth $14,107,000 after purchasing an additional 194,822 shares in the last quarter. Institutional investors own 89.43% of the company's stock.

AngioDynamics Company Profile

AngioDynamics, Inc NASDAQ: ANGO is a medical technology company that develops and manufactures minimally invasive devices used in vascular, oncology, and surgical procedures. Its products are designed to help physicians diagnose and treat vascular disease, remove or manage blood clots, and deliver targeted therapies for certain cancers and other conditions.

The company's product portfolio includes the Auryon Atherectomy System for treating peripheral arterial disease, the AngioVac System for the removal of unwanted intravascular material, and the NanoKnife System, which uses irreversible electroporation to ablate soft-tissue tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.